GSK’s Q3 beat was driven by a strong showing in vaccines – led by Shingrix and the HIV franchise – with healthy support from the other franchises. The 2022 outlook was again revised upwards. While recent (R&D) disappointments along with some past questionable decisions and Zantac uncertainties could again pile pressure on the management, we remain positive on the stock, supported by GSK’s meaningful presence in vaccines and the HIV markets, healthy momentum for the newer drugs and significant po ....
04 Nov 2022
Q3 topped expectations; full-year guidance upgraded
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q3 topped expectations; full-year guidance upgraded
GSK plc (GSK:LON) | 1,638 -245.8 (-0.9%) | Mkt Cap: 67,914m
- Published:
04 Nov 2022 -
Author:
Abhishek Raval -
Pages:
5
GSK’s Q3 beat was driven by a strong showing in vaccines – led by Shingrix and the HIV franchise – with healthy support from the other franchises. The 2022 outlook was again revised upwards. While recent (R&D) disappointments along with some past questionable decisions and Zantac uncertainties could again pile pressure on the management, we remain positive on the stock, supported by GSK’s meaningful presence in vaccines and the HIV markets, healthy momentum for the newer drugs and significant po ....